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Abstract  
 
Background: The efficacy of graded motor imagery (GMI) for the management of complex 
regional pain syndrome (CRPS) is supported by evidence, but its treatment effect remains 
generally modest. Transcranial direct current stimulation (tDCS) has been advocated as an 
adjunct intervention to enhance the effect of motor imagery approaches in pain populations.  
Objective: The purpose of this study was to investigate the effectiveness of GMI + active tDCS 
compared to the GMI + sham tDCS in the treatment of CRPS type I. 
Methods:  22 patients (n=11/group) were randomly assigned to the experimental (GMI + tDCS) 
or placebo (GMI + sham tDCS) group. GMI treatments lasted 6 weeks; anodal tDCS was applied 
over the motor cortex for 5 consecutive days during the first 2 weeks and once a week thereafter. 
Changes in pain perception, quality of life, kinesiophobia, pain catastrophizing, anxiety and 
mood were monitored after 6 weeks of treatment (T1) and 1-month post treatment (T2).  
Results: GMI + tDCS induced no statistically significant reduction in pain compared to GMI + 
sham tDCS. Although we observed significant group differences in kinesiophobia (p=0.012), 
pain catastrophizing (p=0.049) and anxiety (p=0.046) at T1, these improvements were not 
maintained at T2 and did not reached a clinically significant difference.  
Discussion: We found no added value of tDCS combined with GMI treatments for reducing pain 
in patients with chronic CRPS. However, given that GMI + sham tDCS induced no significant 
change, further studies comparing GMI + tDCS and tDCS alone are needed to further document 
tDCS’s effect in CRPS.  
 
Keywords: Complex regional pain syndrome; Non-invasive brain stimulation; Graded motor 
imagery; Pain management.  
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Abbreviations: BDI-II = Beck Depression Inventory; BPI-sf = Brief Pain Inventory short form; 
CRPS = Complex Regional Pain Syndrome; GMI = Graded Motor Imagery; IMMPACT = 
Initiative on Methods, Measurement and Pain Assessment in Clinical Trials; M1 = Primary 
Motor Cortex; MCID = Minimum Clinically Important Difference; MDC = Minimal Detectable 
Change; NRS = numeric rating scales; PCS = Pain Catastrophizing Scale; SF12v2 = SF-12 short 
form; SF-12 MCS = SF-12 mental component summary; SF-12 physical component summary 
(SF-12 PCS); STAI = State-Trait Anxiety Inventory; tDCS = transcranial Direct Current 
Stimulation; TSK = Tampa Scale of Kinesiophobia. 
 
Introduction 
Patients with complex regional pain syndrome (CRPS) present with multiple symptoms, 
including pain, sensory, motor, and trophic changes, associated with an impairment of autonomic 
control of the affected limb. 
1
 The evolution of CRPS symptoms shows high inter-individual 
variability and symptoms can be classified in two phases – acute and chronic. 2 While the 
transition from acute to chronic phase is not precisely determined, it is generally considered to 
occur within three to six months after the onset of the disease. 
2
 The pathophysiology of CRPS is 
debated and there are possibly multiple mechanisms, including inflammation as well as changes 
in sympathetic, peripheral and central nervous systems. 
3,4 
Research using functional imaging 
and electroencephalogram mapping suggests that CRPS may be a result of maladaptive plastic 
changes to the central nervous system. 
5,6
 These studies demonstrated increased overlap between 
the representations of different body parts, potentially related a decrease in intracortical 
inhibition, 
7
 topographical shrinkage in cortical activation, and reduction in the size of the 
somatosensory homunculus (i.e. reduced face-to-hand distance). 
6,8,9
 Hence, modulating cortical 
activity might be a noteworthy therapeutic avenue for individuals suffering from CRPS. 
9–11
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Interestingly, studies using graded motor imagery (GMI) in the treatment of CRPS reported 
positive results, and it has been suggested that the normalization of cortical reorganization seen 
in these patients might be the underlying mechanism to patient recovery. 
4,12,13
 GMI aims to 
activate cortical networks involved in sensorimotor processing in three progressive phases: 1) a 
left-right limb discrimination task (recognition), 2) imagined movements of the affected limb, 
and 3) mirror therapy. 
14,15
 The most recent practice guidelines for the treatment of CRPS state 
that GMI should be used as a first line treatment, 
3
 as evidence shows that a 6-week GMI 
program offers better reduction in pain and improvements in functional gains when compared to 
conventional rehabilitation program. 
14,16,17
 However, despite these positive results, the treatment 
effect size remains modest and for up to a third of the patients, the symptoms of CRPS often 
persist for years. 
13,14,16–18
  Moreover, considering that a recent Cochrane review rated the quality 
of evidence for GMI as low,
19
 it appears appropriate to investigate new therapeutic approaches 
that could enhance current non-pharmacological treatments for CRPS. As suggested by the most 
recent practice guidelines, motor cortex stimulation, through transcranial Direct Current 
Stimulation (tDCS), is as an experimental therapy that could be instated in parallel to GMI. 
3
 
Other studies have shown that the combination of tDCS with a non-pharmacological treatment 
(e.g. visual illusion of walking) in the treatment of neuropathic pain related to spinal cord injury 
resulted in a mean reduction of 29.7% in pain intensity compared to 11.0% to visual illusion 
combined with placebo tDCS. 
20
 Similar results were also observed in a case study involving a 
patient with CRPS type I, which found beneficial effects of tDCS on chronic pain and quality of 
life after the addition of tDCS to sensorimotor rehabilitation. 
21
 To our knowledge, outside these 
discussed there are no other studies that have explored tDCS effects’ in CRPS patients.   
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 Given that a recent Cochrane review
10
 concluded that tDCS may not deliver important benefits in 
chronic pain, a combined approached is justified. Thus, the main goal of this study was to 
explore the effectiveness of anodal tDCS in the treatment of CRPS in addition to GMI on the 
severity of pain in patients with CRPS type I. We hypothesized that the combination of tDCS 
with GMI would lead to better outcomes than GMI alone.  
Materials and methods 
Participants 
In accordance with the Declaration of Helsinki, the study was approved by the Ethics Review 
Boards of the Centre hospitalier universitaire de Sherbrooke and the Hôpital Charles-Le Moyne 
(Québec, Canada). This trial was also registered at ClinicalTrials.gov [NCT01960400]. All 
participants (22 selected out of 62 potential candidates) were patients recruited from the pain 
clinics of these two hospitals and all provided their written informed consent prior to the start of 
the experiment.  Participants received no financial compensation for their participation. Eligible 
patients were (i) aged ≥ 18 years old; (ii) had a medical diagnostic of CRPS type 1 confirmed by 
an anesthesiologist or a neurosurgeon based on Budapest Research Criteria for research 
3
; (iii) 
did not have other chronic pain conditions, dyslexia, visual impairment, neurological, 
psychological or motor disorder; (iv) did not have any history of brain implants, severe head 
trauma or headaches; and finally (v) if the patient was taking pain medication, their 
pharmacological intervention had to be stable (unchanged dose) over the last 4 weeks prior to the 
beginning of the study. Furthermore, participants were required not to modify their 
pharmacological and/or non-pharmacological treatments throughout the 10 weeks of the trial 
(see Table 1 for overview of patient characteristics). 
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Experimental design 
A randomized parallel single blind design including two treatment options was used (GMI + 
active tDCS; GMI + sham tDCS). This design was selected to provide initial evidence regarding 
the effectiveness of the combined treatment for further large-scale studies. 
22
 Since the 
prevalence of CRPS is low, sampling was non-probabilistic and patients consisted of a 
consecutive sample of all eligible patients. After the verification of the admissibility criteria, 
patients were randomly assigned to the experimental group (GMI + active tDCS) or the placebo 
group (GMI + sham tDCS) using a randomized block design, to balance groups in regards to the 
duration of symptoms.  Hence, a list was made for randomization into blocks (2 X 2), one block 
for treatment group and one block for duration of symptoms (≤6 months and >6 months since 
diagnosis of CRPS type 1). In order to avoid a potential concealment bias, the randomization 
sequence was concealed from the investigators, where only an independent research agent held 
the allocation list. The research team did not know the exact size of the blocks until the 
experiment was completed. 
Graded motor imagery (GMI) intervention 
Home exercise: The GMI intervention was performed at home using the Recognise™ Flash 
Cards set, consisting of 25 left and 25 right matching images (upper limb or lower limb) and a 
mirror box (NOIgroup, Adelaide City West, South Australia). The participants performed the 
GMI therapy at home, 10 minutes per session, 3 times per day, 6 times a week, for 6 weeks. 
23
 
The description and settings of the GMI process are detailed in appendix (see Appendix A, 
Supplemental Digital Content 1, http://links.lww.com/CJP/A446 ). Before the beginning of each 
phase, the clinician carefully explained the GMI program to the participant. To further enhance 
standardization, a guide explaining the treatment parameters was given to all participants. 
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Furthermore, at each visit, the GMI program was reviewed with the participant and, if needed, 
the clinician provided the necessary adjustments to follow the standardized application of the 
program. 
Transcranial direct current stimulation (tDCS) intervention 
Interventions in the experimental (clinical) settings: tDCS was delivered according to the method 
described by Fregni et al. (2006) 
24
 and in accordance with the safety guidelines related to tDCS 
application. 
25
 Direct current was delivered using a battery-driven constant current stimulator 
(DC-Stimulator NeuroConn, Germany) coupled to saline-soaked (0.9% NaCl) sponge electrodes 
(5 X 7 cm). Anodal stimulation was delivered over M1; the anode was placed over C3 or C4 
position in the 10/20 system) for the EEG electrode position, contralateral to the affected limb, 
and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). 
25
 The 
choice of stimulation sites and stimulation parameters was based on previous studies showing 
improvement of neuropathic pain conditions. 
20,27
 A constant current of an intensity of 2 mA was 
applied for 20 minutes (30 seconds ramp up, 30 seconds ramp down), each day, for five 
consecutive days (Monday to Friday) during the first and the second weeks of GMI (see Fig. 
1A). To help retain the potential effects of the neurostimulation, the tDCS was also applied 
simultaneously with GMI once a week (Mondays) during the two other phases until the end of 
the six weeks GMI program, for a total of 14 treatment sessions. For the group receiving the 
sham tDCS, the electrodes were placed in the same position as for the active stimulation using 
the same tDCS stimulator at same stimulation intensity (2 mA), but the device automatically 
turned off after 30 seconds of stimulation (placebo mode). This type of sham stimulation has 
been shown to reliably blind subjects. 
26
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Timing of GMI and tDCS interventions 
All combined GMI and tDCS intervention occurred in the experimental (clinical) setting.  During 
weeks 1 and 2 (Monday to Friday), the first GMI treatment of the day was combined with tDCS; 
the other two prescribed GMI treatments for that day were performed at home. In addition, on 
Saturday or Sunday, participants realized the GMI program three times per day (a total of 10 
treatments combined in laboratory and 26 treatments GMI at home). For weeks 3 to 6, GMI + 
tDCS treatments were done on Monday mornings, and all other daily GMI sessions were 
undertaken by the patient at home, for a total of 4 treatments combined in laboratory and 68 GMI 
sessions at home (see Figure 1a). 
Accordingly, when patients were present in the experimental setting, the tDCS was installed and 
started. After 8 minutes of stimulation (out of 20), they were asked to start performing the GMI 
exercises (see Figure 1b). This was based on the observations of Nitsche & Paulus, who found 
that anodal stimulation of about 9 to 13 minutes leads to a more robust and long-lasting increase 
in cortical excitability. 
28
  
Fidelity of the intervention: 
In order to ensure the fidelity of the application of the combined treatment within the three 
clinicians, and to ensure that the results obtained were dependent on the intervention and not on 
the clinician, specific strategies were put in place: 1) the production of an application guide - as 
recommended by Sidani & Braden
29
 - containing a detailed description of the combined 
interventions, the materials needed and the procedure to be followed by the research team 
members, 2) a priori standardization of clinicians and 3) individual follow-up of the intervention 
for each participant by the lead investigator (EL).   
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Outcome measures (dependent variables) 
The choice of the outcome measures was made in accordance with the Initiative on Methods, 
Measurement and Pain Assessment in Clinical Trials (IMMPACT) guidelines 
30
 and included 
measures of pain severity and interference with function. All patients completed a self-
administered questionnaire to assess the clinical characteristics of pain. Measurements took place 
before (T0), after 6 weeks of treatment (T1) and 1 month after the end of the treatment (T2). The 
primary outcome measure was pain severity and measured by the Brief pain inventory short-
form (BPI-sf). 
31
 The BPI-sf includes four questions on pain levels, where subjects were asked to 
rate intensity on a scale of 0 (no pain) to 10 (worst possible pain) in regards to: 1) pain at its 
worst in the last 24 hours, 2) pain at its least in the last 24 hours, 3) average pain over the last 24 
hours and 4) pain right now (present pain). The score of each subscale ranges from 0 to 10 for a 
total score of 40. The minimum clinically important difference (MCID) is an average score of 
>2/10 for each of the four subscales). 
32
 The following secondary outcome measures were also 
assessed. 
Impact of pain on daily function 
The BPI-sf also had 7 questions measuring the impact of pain on daily function, including the 
impact on general activity, sleep, mood, enjoyment of life, walking ability, ability to work and 
perform daily tasks and relationships with other people. 
33
 Subjects were asked to rate how their 
pain interfered with these items over the previous 24h using a numerical rating scale (NRS) 
ranging from 0 (does not interfere) to 10 (completely interferes). The total score of this section of 
the BPI-sf ranges from 0 to 70. 
Quality of life 
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The SF-12 short form (SF12v2) 
34
 is a general health-related quality of life questionnaire that 
consists of 12 Likert scale questions derived from the original SF-36 questionnaire. 
35
 It covers 
eight domains (i.e., physical functioning, role-physical, bodily pain, general health, vitality, 
social functioning, role-emotional and mental health). The scores on each of these domains are 
summarized into two scales: the SF-12 physical component summary (SF-12 PCS) and the SF-
12 mental component summary (SF-12 MCS). Scores for each summary scale, ranging from 0 to 
100, were calculated with standard scoring algorithms and normalized using the US general 
population values [mean 50 (S.D. 10)], with lower scores indicating worse health-related quality 
of life. 
35
 The MCID for the SF-12 PCS is ≥8.8/100 and ≥9.3/100 for the SF-12 MCS. 36 
Kinesiophobia 
The Tampa Scale of kinesiophobia (TSK), 
37
 a 17-item self-report measure, was used to assess 
fear of movement and injury/(re)injury. The total score ranges from 17 to 68, with higher scores 
representing stronger fear-avoidance beliefs. 
38
 The minimal detectable change (MDC) for the 
TSK is >4.8. 
39
 
Pain Catastrophizing 
The Pain catastrophizing scale (PCS) 
40
 was used to evaluate the feelings, thoughts, and emotions 
related to pain catastrophizing. It is a self-administered questionnaire consisting of 13 items 
included in three subscales. The total score ranges from 0 to 52 points, with higher scores 
representing stronger pain catastrophizing. 
40
 The MDC for the PDC is >9.1. 
39
 
State Anxiety  
The State-Trait Anxiety Inventory (STAI) 
41
 is used to assess the state of anxiety at the moment. 
42
 The total score ranges from 20 to 80, where higher total score is, higher is the anxiety about an 
event. 
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Symptoms of depression 
The Beck Depression Inventory (BDI-II), 
43
 which includes 21 statements, was used to measure 
symptoms and attitudes specific to depression. 
44
 Each statement is graded from 0 to 3, and 
higher total score indicates more severe depressive symptoms. The MCID is a ≥17.5% reduction 
from baseline (≥11/63). 45 
Measures of compliance, adverse effects and blinding 
The completion of a daily diary at home by all the patients throughout the study enabled us to 
monitor the implementation of the GMI program as well as compliance. Patient blinding was 
assessed at the end of the trial by asking each patient to guess which treatment they believed to 
have received. Throughout and after all the GMI or tDCS treatments, patients were also asked to 
note and report any side effects they experienced. 
Statistical analysis 
Sample size estimates were based on the results of the study of Soler et al. (2010), 
20
 which 
aimed to evaluate the efficacy of tDCS combined with another treatment modality, the visual 
illusion of walking. In their study, the severity of pain, assessed using a numerical scale from 0–
10, had an average reduction of 29.7 ± 5.0% for the tDCS + visual illusion of walking group, 
compared to an average reduction of 11.0 ± 14.0% for the sham tDCS + visual illusion of 
walking after treatment. To consider that there is a significant difference between both groups, 
pondering that the average percentage of pain relief would be 29.7% for the experimental group 
and 11.0% for the placebo group, we estimated a mean difference of ~ 20% between groups, 
with a standard deviation of 14.0% (α = 0.05 and β = 1 to 0.80).  Hence, the sample size of each 
group was estimated at 10 participants. Considering a dropout rate of 10%, a total of 11 
participants per group were recruited. 
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At T0, the normality of the data (sociodemographic characteristics and dependent variables) was 
first tested using the Kolmogorov-Smirnov test. According to the results, either parametric tests 
(Student's T tests; normal distribution) or non-parametric tests (Wilcoxon signed-rank tests; 
asymmetric distribution) were performed. For categorical data, the chi-square tests or Fisher 
exact tests (if frequency of a cell of the crosstab was five or less) were used to compare outcomes 
between the two groups. 
To compare the effectiveness of interventions (between-group differences), a mixed-model 
ANOVA (time X group interaction) was used. Due to a difference in total duration of each 
measurement time (T0 - T1 = six weeks; T1 - T2 = four weeks), a simple contrast (versus T0) 
and non-polynomial analysis was selected from the IBM SPSS software. Age, as a covariate was 
included in the model, since it was found to be significantly different between both groups in 
order to obtain an adjusted p-value. However, for all the continuous dependent variables, age did 
not significantly impact the results and therefore were not retained. To compare the percent of 
change of each individual against the recognized MCID, defined as the statistically determined 
smallest change in a treatment outcome to be identified as important for the patients, 
46
 we used 
the Fisher's exact test for between groups comparison at T1 and T2. All statistical analyzes were 
performed using IBM SPSS Statistics 22.0 version of Mac OS and Graph Pad Software (2015) 
(http://www.graphpad.com/quickcalcs/). 
Results 
Descriptive data 
All subjects were enrolled between May 2012 and June 2014. Figure 2 shows the CONSORT 
flowchart for our study. Twenty-two patients, all meeting the admissibility criteria, were 
included. 
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At baseline (T0), sociodemographic and clinical characteristics of both groups did not differ 
significantly (see Table 2), except for the mean age in the experimental group (40.91 years ± 
8.83) versus for the placebo group (52.73 years ± 10.48) (p=0.029). The mean duration of 
symptoms did not differ between both groups (experimental group: 36.27 months ± 25.62; 
placebo group: 36.55 months ± 25.79) (see Table 1).  
Primary outcome measure: Pain severity (BPI-sf) 
Overall, change in pain severity (BPI-sf) did not significantly differ between groups, where only 
a tendency was observed (p=0.065) (see Table 2). The only Group X Time interaction was found 
in the subscale measuring pain severity (present pain p=0.046), which was not maintained at the 
one-month post-intervention (T2) (see Figure 3). Also, no difference in the proportion of patients 
who reached the MCID threshold was found between both groups at T1 and at T2, even for the 
present pain subscale, where a 42% reduction in present pain intensity was observed at T1 for the 
experimental group. 
Secondary outcome measures 
Complete results for the secondary variables are also presented in Table 2. We found no 
significant between group differences (time X group interaction) at T1 and T2 regarding the 
impact of pain on global physical functioning, on the physical and mental health quality of life 
and on depressive symptoms. No difference in the proportion of patients who reached the MCID 
threshold was found between both groups for either variable, at T1 and at T2. For the fear of 
movement, pain catastrophizing and state anxiety, the analysis revealed a statistically significant 
time X group interaction at T1 only, which showed lower scores for the experimental group.  
However, these were not maintained at T2. Yet, considering that the group differences for the 
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first two variables are less than the known MDC, it certainly did not reach a clinically significant 
level and has to be interpreted with caution.  
Assessment of compliance and blinding 
In regards to compliance, we noted from the daily diary that all participants reported completing 
their GMI sessions 3 times per day, 6 times a week, for 6 weeks.  Finally, all patients completed 
the 14 treatments of tDCS in the laboratory setting. 
At the end of the treatments (T1), participants were asked in which treatment group they believed 
they were allocated (experimental or placebo). Thirteen participants (59.1%) responded 
correctly. Nine participants (81.8%) from the experimental group compared with seven 
participants (63.6%) from the placebo group responded that they had received the active tDCS 
treatment regimen. No statistically significant difference was found between groups in the 
assessment of blinding (p=0.635). 
Adverse effects of treatment 
Regarding the undesirable effects of the GMI treatment, three participants reported that specific 
images had generated a temporary increase in pain (~ 30 minutes), mainly during the phase 2 of 
the protocol. Two strategies were proposed to these participants: to remove the images that 
provoked pain and to reduce the time of subsequent sessions (before the onset of pain). Only one 
participant from the experimental group reported minor fasciculation during the exercises in 
Phase 3. As a strategy to avoid this discomfort, the participant was invited to perform his 
exercises more slowly, by granting short breaks of a few seconds. Regarding the undesirable 
effects of the tDCS, three participants from the experimental group and two participants from the 
placebo group complained of minor headaches after tDCS, especially during the second week of 
Phase 1. In all cases, the headaches disappeared within two or three hours following the tDCS 
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session. These participants reported taking acetaminophen after their tDCS session, which had a 
beneficial effect on their headaches. Only one participant from the experimental group reported a 
slight reddening and itching on his head (around the location of the anode) during the second 
week of treatment. Two participants from the experimental group and one participant of the 
placebo group reported feeling more tired than usual on a number of occasions after their tDCS 
treatment. Finally, four participants (18.2%) declared having been indisposed by a sting/burning 
sensation under the electrodes during the first minute of active tDCS. Adding saline water (~ 5 
ml per electrode) and applying a slight pressure on the electrodes immediately reduced this 
discomfort. No tDCS sessions were interrupted due to undesirable or adverse effects.   
Discussion 
The main objective of this study was to produce preliminary evidence regarding the therapeutic 
effectiveness of the combination of GMI and tDCS for the management of CRPS. In regards to 
our main outcome measure (pain severity), we found no statistically significant group differences 
immediately and 1 month after the 6 weeks of treatment. Yet, considering that a tendency was 
observed (p=0.06) and that for one subscale of our main dependent variable a positive outcome 
was found, our results may suggest that this treatment regimen could induce positive outcomes 
on a very short-term perspective. Considering this tendency, a larger sample-size, thus greater 
power, could have lead to a true and significant effect. However, although stronger than GMI 
alone, these observations lead us to believe that, in our sample, the analgesic effects of GMI + 
tDCS are modest at the very and also very short-lived. As for group differences in regards to 
kinesiophobia, pain catastrophizing and state anxiety following 6 weeks of GMI + active tDCS, 
they need to be interpreted with caution since none reached a clinically significant difference. 
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Short-term benefits of GMI + active tDCS 
The combination GMI + active tDCS (experimental group) resulted in a 42% reduction of 
present pain intensity scores at T1; considering this change is greater than ~30%, it represents a 
clinically important difference. 
47
 In comparison, this positive short-term effect is somewhat 
comparable to the 29.7% pain reduction obtained by Soler et al. (2011) 
20
 with a comparable 
treatment approach (tDCS + visual illusion of walking), but in a different neuropathic pain 
population. However, this pain reduction should be interpreted with caution, as the effect is 
dependent on a subscale of only one of our main variable. In fact, the lack of significant effect in 
our main variable (pain severity) appears to be more similar to reports of a recent Cochrane 
systematic review, which concludes that tDCS may not deliver statistically significant effects in 
individuals with chronic pain. 
10
 However, since we observed no changes in the placebo group 
(sham tDCS) – pain reduction was only observed in the experimental group (active tDCS) - the 
specific effects of the tDCS could explain the greater analgesia in present pain observed at T1. 
Given our results, a third group, which would have only received the active tDCS without GMI, 
could have helped us to determine the indebted effect specific to the tDCS. However, this was 
not performed due to: 1) the explorative nature of the study (proof of concept), 2) the feasibility 
issues in terms of recruiting participants and 3) ethical reasons given that GMI is recommended 
in current CRPS practice guidelines, 
3
 it would have been arguable to provide only a treatment 
which is supposed to be an add-on to our patients. The effect of tDCS on present pain 
management could be an avenue to explore further, as the effect of tDCS was only sustained in 
the short term. 
Lack of pain reduction one month after treatment (T2)  
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For the management of pain, the most commonly used protocol consisted of 20-min anodal 
stimulation of M1 for five consecutive days, which may lead to significant analgesic after-effects 
lasting for 2-6 weeks. 
48
 According to the same parameters, the application of 10 sessions of 
anodal tDCS should generate long-lasting analgesic effects, up to 60 days after the end of 
treatments. 
27
 However, although this dosage was observed in addition to a weekly session until 
the end of GMI treatment, the results we obtained (GMI + tDCS) did not demonstrate a 
significant analgesic after-effect lasting one month post-intervention. 
An element that could explain the overall lack of effect might be related to anticonvulsants that 
might have decreased the effects of anodal stimulation after a single session of tDCS. 
49
 This 
lack of pain reduction observed might suggest that patients with anticonvulsants may respond 
less to this treatment. In fact, 73% and 64% of the patients took anticonvulsants in the 
experimental and placebo groups, respectively, which could potentially have lessened the tDCS 
effect. 
49,50
 In order to increase the effect and the chances of longer-lasting pain relief, perhaps a 
more adequate and/or personalized pharmacological approach could help modulate treatment 
effects, 
51
 a factor that was not manipulated in our study, but only partially controlled.  
Lack of treatment effect in the placebo group 
Although not the main focus of our study, the absence of a "no-treatment" group also forbids us 
to draw any clear conclusion to answer questions regarding if GMI alone (placebo group) was 
helpful, harmful or of no value. However, participants in the placebo group (GMI + sham tDCS) 
showed no positive treatment effect, which again is in discordance to the results of some 
previously published studies, who found a reduction in pain intensity after GMI alone. 
14,16,17
 
This lack of effect of the GMI observed in our study could partly be explained by two factors: 1) 
duration of CRPS symptoms: although the distribution of participants in the two groups 
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(experimental and placebo) during randomization was successful, our "chronic" CRPS patients 
all had a much longer duration of symptoms (~ 36 months) compared to the participants in 
Moseley’s previous publications (~ 14 months). 14,16,17 Studies from other groups also reported 
poor results with the use of GMI for chronic CRPS patients. For instance, McCabe et al. 
52
 found 
an immediate analgesic effect using mirror therapy on acute-subacute CRPS patients, but 
reported no positive effect for chronic CRPS patients (> 14 months). The same observations 
were reported by Johnson et al., 
53
 who even reported an increase in pain of +37.5% during GMI 
for their chronic CRPS patients (~ 23 months). Hence, it appears that GMI has equivocal results 
for patients with a longer duration of CRPS and clearly needs further investigation. 2) minor 
discrepancies between treatment regimen: the other factor that could explain the absence of 
treatment effect for the placebo group may be related to our GMI intervention protocol, which 
somewhat varied from the one used in Moseley’s published clinical trial 17 (see Appendice A for 
comparisons); our recommended frequency for GMI exercises was lower (3 exercise sessions per 
day) than Moseley’s hourly recommendation. 14,16,17 But many audited patients in these previous 
studies reported that complying with exercises every waking hour was not feasible for them 
(75% compliance rate was reported). Our methodological choice regarding the frequency of the 
exercises was based on previous positive findings 
23
 and the fact that this exercise regimen was 
more respectful of their daily routine and quality of life during the intervention. 
29,54
 This 
methodological choice also probably contributed to the perfect compliance we observed for our 
two groups. Nevertheless, the lower frequency of the exercises remains a possible explanation of 
the lack of result of the GMI.  
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Finally, another possible explanation for the lack of effect in our placebo group is related to the 
absence of progression of the training load. The use of software proposed by Moseley (2006) 
17
, 
instead of Recognise™ Flash Cards, would have made it possible to graduate the requirements of 
the exercises. However, the parameters of use of the GMI are not entirely known and are difficult 
to reproduce. In short, further investigations are required to determine if the NOI group’s 
Recognise™ Flash Cards provide equivalent results to the use of the adaptive software. 
Knowing that 1) the effectiveness of GMI has been demonstrated by three separate trials of GMI, 
all conducted by the same research team and 2) all were relatively small trials (13 to 37 
participants), a high risk of bias may be present.
19
 In fact, another independent research team 
could not, as in our study, confirm the effectiveness of the GMI. 
53
 Failure of the real-world 
implementation of GMI suggests that better understanding of both GMI methodology and its 
interaction with other treatment modality is required to ensure that GMI research results can be 
translated into clinical practice. Further studies would be necessary to determine the optimal 
frequency of exercises, while considering its pragmatic application in real-life. 
Potential bias related to the blinding procedures 
When we initially developed this protocol, we relied on the most robust available evidence to 
develop the tDCS protocol. It was then accepted that the use of a 2 mA stimulation presumed an 
effective blinding 
20,21,27
. But recently, O'Connell et al. (2012) 
55
 demonstrated that a 2 mA tDCS 
might not be associated with effective blinding when compared with the sham commonly using 
this procedure. Since our study had reported superior efficacy of active stimulation over sham 
and adequate participant blinding, assessor blinding was not possible. While we cannot predict 
the degree of influence that inadequate blinding may have had in our study, non-specific effects 
of interventions are known to be important in such clinical conditions. 
56,57
 Further, there is 
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evidence that incomplete blinding leads to exaggerated effects in clinical studies with subjective 
outcomes, 
58
 and that placebo effects are larger with physical placebo interventions. 
57
  Thus, the 
O'Connell study 
55
 contends that clinical studies that have used 2 mA tDCS should be interpreted 
with renewed caution. Using intensities of 1 mA in future research may represent a more 
methodologically sound option, although it is plausible that reducing the intensity may reduce 
potential efficacy. Future studies of tDCS may benefit from other methods to optimise blinding, 
for example de facto masking in which the treatment is not blinded but both treatments are 
presented as the active one. 
59
 
Future considerations 
Maybe better outcomes could be obtained if the treatment was individually adjusted according to 
the main neurophysiological process that explains the development and/or maintenance of CRPS 
symptoms, i.e. peripheral vs. spinal vs. central hypersensitivity or sympathetic neural system. 
1
 
Based on the principle that management of painful pathologies should be incorporated within a 
biopsychosocial framework, patients could be offered treatments grounded on the multiple 
different mechanisms driving pain and disability. Maybe, in our protocol, too much emphasis 
was directed towards nervous system hypersensitivity (GMI and tDCS mostly target supra-spinal 
hypersensitivity) and less on cognitive-emotional factors (i.e.: psychogenic drivers of pain or 
pain avoidance-behaviors) or environmental factors, such as attitudes of others or beliefs 
regarding work.  It is possible that a patient-centered approach, based on how the person 
responds to treatment with the addition of other targeted therapeutic modalities, could induce a 
more efficient management of CRPS. 
60
 Also, further investigations are required to elucidate the 
elements of GMI intervention that determine success and to identify the characteristics of 
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responders. A better understanding of the relative weight of this each factor could allow to better 
personalizing the treatment protocol.  
Conclusions 
The current report was the first to investigate the added-value of tDCS to GMI in the treatment 
of CRPS type I. Our results show no significant added value of adding a series of tDCS in 
addition GMI treatments for reducing pain severity in patients with chronic CRPS type I. 
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Table 1. demographic and clinical characteristics of the patients  
Gender Age 
(years
) 
Time 
since Dx 
CRPS 
(months) 
Affected 
limb 
Initial event Pain level 
baseline 
mean 
(/10) 
Pain medication 
 
Graded Motor Imagery (GMI) group + active transcranial Direct Current Stimulation (tDCS)  
Female 27 13 Right hand Sprain grade 2 5 PGB, ACE, NSAID, ANT 
Male
 
 39 39 Left foot Sprain grade 2 5 PGB, ANT 
Female
 
 51 19 Right arm Electrification 8 PGB, NSAID, BZD, 
ANT, BZD, CAL 
Female
 
 45 23 Left hand Amputation distal 
thumb  
3 INN 
Female
 
 49 5 
**
 Left arm Wrist fracture 4 GBP, ACE 
Female
 
 53 127 Right arm Repetitive movement 6 PGB, TMD, ANT 
Female 43 5 
**
 Left foot
 
Sprain and 
microfracture 
2 PGB, TMD 
Female 22 72 Right hand Shoulder 
hyperextension 
7 CAL, NAB, PGB, TMD 
Female
 
 37 48 Right leg Minor trauma 6 None 
Male 31 23 Left knee Patella fracture 7 GBP, BZD 
Male 53 25 Right foot Medial malleolus 
fracture 
6 BZD 
F: 8     M: 3 41 ± 9 36 ± 26 R: 4(U); 2(L) 
L: 2(U); 3(L) 
 4.9 ± 1.8  
 
Graded Motor Imagery (GMI) group + sham transcranial Direct Current Stimulation (tDCS)  
 
Female 
 
63 92 Right arm Wrist fracture 7 None 
Male  58 3 
**
 Left hand
 
Cyst ablation 6 GBP, PGB, COD 
Male
 
 46 36 Left foot Sprain and avulsion 8 PGB, ANT, ACE, 
NSAID, KTMt 
Female
 
 56 77 Left arm Wrist tendinitis 8 BZD, INN, CBZ, ANT 
Female
 
 46 50 Right hand Minor trauma 7 ANT, CBZ 
Female 35 19 Left foot Crush and sprain 6 INN, BZD, KTMt 
Male 60 26 Right foot Toe fractures 6 ANT, TMD, BZD, PGB 
Male 78 69 Left hand Amputation index 
finger 
3 BZD, PGB, TMD 
Female 59 16 Right hand Carpal tunnel surgery 4 PGB, ANT 
Female 42 10 Right hip Hip fracture  4 TMD, PGB, OXT 
Male 37 4 
**
 Left foot
 
Ankle sprain and 
fracture 
7 KTM, PGB, FE 
F: 6 
M: 5 
53 ± 
10 
37 ± 26 R: 3(U); 2(L) 
L: 3(U); 3(L) 
 6.0 ± 2.4  
Notes. ** = less than six months; Dx = diagnosis. Sex: F = female; M = male. Affected 
limb: U = upper; L = lower. Pain medication: ACE = acetaminophen; ANT = 
antidepressive; BZD = benzodiazepine; CAL = calcitonin; CBZ = cyclobenzaprine; CNZ = 
clonazepam; COD = codeine; FE = fentanyl; GBP = gabapentin; INN = morphine; 
KTM(t)= ketamine (topic); NAB = nabilone; NSAID = nonsteroidal anti-inflammatory 
drug; OXT = oxycodone; PGB = pregabalin; TMD= tramadol. 
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Table 2. Group comparison at T0-T1-T2 and effectiveness of the intervention (time X group interaction) 
 
Variables  
Baseline measurements (T0)  After 6 weeks of treatments (T1)  1 month after the end of 
treatments (T2) 
Experime
ntal group  
(mean ± 
SD) 
Placebo 
group 
(mean ± 
SD) 
 
p-
valu
e a 
Experimen
tal group 
(mean ± 
SD) 
Placebo 
group 
(mean ± 
SD) 
 
p-
valu
e a 
 
p-
valu
e b 
Experime
ntal group 
(mean ± 
SD) 
Placebo 
group 
(mean ± 
SD) 
 
p-
valu
e a 
 
p-
valu
e b 
Pain 
severity  
 
Present 
pain 
Average 
pain 
Most 
intense pain 
Least 
intense pain 
22.18±7.4
3 
 
5.95 ± 
2.21 
4.92 ± 
1.80 
7.27 ± 
1.79 
4.09 ± 
2.17 
23.36±6.
19 
 
6.09 ± 
1.51 
6.00 ± 
2.35 
7.18 ± 
1.89 
4.09 ± 
2.21 
0.6
89 
 
0.4
40 
0.4
01 
0.9
09 
1.0
00 
18.00±9.2
0 
 
4.18 ± 
2.48 
4.64 ± 
2.20 
5.27 ± 
2.37 
3.91 ± 
2.43 
23.82±5.
93 
 
6.18 ± 
1.25 
5.73± 
1.49 
6.82 ± 
1.89 
5.09 ± 
1.87 
0.09
3 
 
0.02
7* 
0.18
9 
0.10
6 
0.21
5 
0.06
5 
 
0.04
6* 
0.38
1 
0.06
4 
0.14
2 
19.27±9.1
8 
 
4.73 ± 
2.69 
4.91 ± 
2.21 
6.09 ± 
2.51 
3.55 ± 
2.25 
21.09±6.
20 
 
4.91 ± 
2.17 
5.55 ± 
2.02 
6.55 ± 
2.91 
4.09 ± 
1.92 
0.5
92 
 
0.8
63 
0.4
89 
0.6
99 
0.5
48 
0.7
71 
 
0.5
95 
1.0
00 
0.5
74 
0.4
85 
 
Impact of 
pain on 
physical 
functioning 
 
 
 
38.36±15.
96 
 
 
37.45±17
.49 
 
 
0.9
00 
 
 
28.10±19.
77 
 
 
36.27±14
.73 
 
 
0.28
4 
 
 
0.15
4 
 
 
28.82±19.
32 
 
 
34.00±18
.04 
 
 
0.5
23 
 
 
0.3
81 
 
Quality of 
life 
Physical 
health 
Mental 
health  
 
 
32.24±7.8
3 
41.79±12.
19 
 
 
 
31.48±7.
63 
38.84±11
.16 
 
 
0.8
21 
0.5
60 
 
 
33.52±7.0
5 
46.81±9.7
9 
 
 
32.16±8.
01 
42.04±13
.09 
 
 
0.67
8 
0.34
4 
 
 
0.82
9 
0.60
3 
 
 
37.11±7.9
4 
45.40±9.7
5 
 
 
34.18±9.
75 
44.18±13
.98 
 
 
0.4
49 
0.8
20 
 
 
0.5
74 
0.6
85 
 
Kinesiopho
bia 
 
44.09±8.6
0 
 
 
42.55±8.
59 
 
0.6
78 
 
40.36±8.2
3 
 
42.82±8.
27 
 
0.49
3 
 
0.03
5* 
 
41.55±11.
47 
 
41.36±7.
84 
 
0.9
66 
 
0.6
61 
 
Pain 
catastrophi
zing 
 
24.09±10.
98 
 
27.64±10
.36 
 
0.4
45 
 
16.64±10.
68 
 
25.91±11
.42 
 
 
0.06
3 
 
0.04
9* 
 
18.27±12.
05 
 
22.82±13
.35 
 
0.4
12 
 
0.7
76 
 
 
 
State 
anxiety 
 
41.91±14.
43 
 
41.91±17
.61 
 
1.0
00 
 
35.91±12.
19 
 
44.00±15
.38 
 
0.18
7 
 
0.04
6* 
 
36.91±11.
73 
 
42.09±17
.38 
 
0.4
22 
 
0.0
84 
 
 
Symptoms 
of 
depression 
 
15.45±8.6
9 
 
16.91±9.
97 
 
0.7
19 
 
11.09±5.4
5 
 
16.27±10
.02 
 
0.14
8 
 
0.18
3 
 
10.27±7.0
4 
 
14.00±7.
67 
 
0.2
49 
 
0.3
04 
 
Notes. *p<0,05. 
a
 Group comparison at a given measuring time; 
b
 Between group comparison (Group x 
Time interaction) 
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Figure 1. Experimental design 
(a) Experimental design for each phase of GMI plus tDCS stimulation for the 6 weeks of 
treatment. (b) Timing of the application protocol of tDCS during GMI for the 14 
treatments that occurred in the experimental settings. 
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Figure 2. CONSORT flow chart 
 * n=12 with CRPS type 1 who did not fulfill recognized diagnostic criteria, n=7 with unstable 
medication; ** n=3 with other chronic pain, n=1 with unstable medical condition, n=2 with head 
trauma, n = 1 with frequent severe headaches, n=2 with epilepsy. GMI = Graded Motor Imagery; 
tDCS = transcranial Direct Current Stimulation. 
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Figure 3. Progression of Present Pain intensity scores through time for both groups  
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